In addition to the improvement of HF-related outcomes, the risk of major adverse events is also reduced with SGLT2 inhibition.<h4>Systematic review registration</h4>[www.ClinicalTrials.gov], identifier [CRD42022358078]. This evidence concerns the gene SLC5A2 and hydrops fetalis.